69,034 Shares in Novavax, Inc. (NASDAQ:NVAX) Acquired by Twinbeech Capital LP

Twinbeech Capital LP bought a new position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 69,034 shares of the biopharmaceutical company's stock, valued at approximately $555,000.

Several other institutional investors and hedge funds have also bought and sold shares of NVAX. Spire Wealth Management bought a new position in shares of Novavax in the fourth quarter worth $29,000. New Age Alpha Advisors LLC purchased a new position in shares of Novavax during the fourth quarter worth about $35,000. KBC Group NV increased its position in shares of Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 3,917 shares during the last quarter. TigerOak Management L.L.C. purchased a new stake in Novavax in the fourth quarter valued at approximately $86,000. Finally, AlphaQuest LLC raised its stake in Novavax by 290.1% in the fourth quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 7,940 shares in the last quarter. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Novavax Stock Up 1.6%

Shares of NASDAQ NVAX traded up $0.12 during midday trading on Tuesday, hitting $7.37. The stock had a trading volume of 5,493,867 shares, compared to its average volume of 6,864,648. The business's 50 day moving average is $6.60 and its 200-day moving average is $7.81. Novavax, Inc. has a 52 week low of $5.01 and a 52 week high of $23.86. The company has a market cap of $1.19 billion, a P/E ratio of -3.25, a PEG ratio of 2.85 and a beta of 3.21.

Novavax (NASDAQ:NVAX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $2.22. The business had revenue of $666.66 million during the quarter, compared to the consensus estimate of $204.08 million. During the same period last year, the company posted ($1.05) earnings per share. The business's revenue was up 610.3% compared to the same quarter last year. As a group, analysts expect that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NVAX. TD Cowen upgraded Novavax to a "hold" rating in a report on Thursday, February 27th. JPMorgan Chase & Co. decreased their price objective on shares of Novavax from $9.00 to $7.00 and set an "underweight" rating on the stock in a research report on Friday, May 9th. BTIG Research initiated coverage on Novavax in a report on Friday, February 28th. They set a "buy" rating and a $19.00 target price for the company. Finally, B. Riley reissued a "buy" rating on shares of Novavax in a research note on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $19.00.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.